BRPI1002087B1 - Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica - Google Patents

Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica Download PDF

Info

Publication number
BRPI1002087B1
BRPI1002087B1 BRPI1002087-0A BRPI1002087A BRPI1002087B1 BR PI1002087 B1 BRPI1002087 B1 BR PI1002087B1 BR PI1002087 A BRPI1002087 A BR PI1002087A BR PI1002087 B1 BRPI1002087 B1 BR PI1002087B1
Authority
BR
Brazil
Prior art keywords
aat
cfs
alpha
chronic fatigue
treatment
Prior art date
Application number
BRPI1002087-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Garcia Quintana
José Alegre Martin
Original Assignee
Grifols, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols, S.A. filed Critical Grifols, S.A.
Publication of BRPI1002087A2 publication Critical patent/BRPI1002087A2/pt
Publication of BRPI1002087B1 publication Critical patent/BRPI1002087B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI1002087-0A 2009-06-30 2010-06-24 Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica BRPI1002087B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (2)

Publication Number Publication Date
BRPI1002087A2 BRPI1002087A2 (pt) 2012-03-13
BRPI1002087B1 true BRPI1002087B1 (pt) 2019-07-02

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1002087-0A BRPI1002087B1 (pt) 2009-06-30 2010-06-24 Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica

Country Status (16)

Country Link
US (1) US9205134B2 (https=)
EP (1) EP2289540B1 (https=)
JP (1) JP5231490B2 (https=)
CN (1) CN101934071B (https=)
AR (1) AR077123A1 (https=)
AU (1) AU2010202203B2 (https=)
BR (1) BRPI1002087B1 (https=)
CA (1) CA2706212C (https=)
CL (1) CL2010000575A1 (https=)
ES (2) ES2332645B1 (https=)
MX (1) MX2010006125A (https=)
NZ (1) NZ585890A (https=)
PL (1) PL2289540T3 (https=)
PT (1) PT2289540E (https=)
RU (1) RU2436590C1 (https=)
UY (1) UY32670A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793936A4 (en) * 2011-12-19 2015-05-27 Lfb Usa Inc RECOMBINANT HUMAN ALPHA-1-ANTITRYPINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CN1450898A (zh) * 2000-04-21 2003-10-22 法玛西雅厄普约翰美国公司 用于治疗纤维肌痛和慢性疲劳综合症的化合物
US20040043510A1 (en) * 2000-07-14 2004-03-04 Nobuyuki Shigetoh Particle-labeled protein and immuno-chromatograph using the same
CA2506839A1 (en) 2002-11-20 2004-06-03 Prometic Biosciences, Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) * 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
WO2008143633A2 (en) * 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
PL2214699T3 (pl) 2007-11-02 2017-05-31 Grifols Therapeutics Inc. Sposób, kompozycja i wyrób do dostarczania alfa1-antytrypsyny

Also Published As

Publication number Publication date
CA2706212C (en) 2014-02-04
ES2332645B1 (es) 2010-10-18
ES2392691T3 (es) 2012-12-12
MX2010006125A (es) 2011-01-05
NZ585890A (en) 2011-11-25
EP2289540A1 (en) 2011-03-02
ES2332645A1 (es) 2010-02-09
HK1148198A1 (en) 2011-09-02
UY32670A (es) 2011-01-31
CL2010000575A1 (es) 2011-10-28
CA2706212A1 (en) 2010-12-30
RU2436590C1 (ru) 2011-12-20
AU2010202203B2 (en) 2012-08-23
EP2289540B1 (en) 2012-08-22
JP5231490B2 (ja) 2013-07-10
US9205134B2 (en) 2015-12-08
US20100331261A1 (en) 2010-12-30
AR077123A1 (es) 2011-08-03
JP2011012060A (ja) 2011-01-20
CN101934071B (zh) 2012-11-28
BRPI1002087A2 (pt) 2012-03-13
CN101934071A (zh) 2011-01-05
PL2289540T3 (pl) 2013-03-29
PT2289540E (pt) 2012-12-04
AU2010202203A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
Oguz et al. The use of hyperbaric oxygen therapy in ophthalmology
Sánchez-Aguilar et al. Effect of rosuvastatin on cytokines after traumatic head injury
BRPI1002087B1 (pt) Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica
Zheng et al. Posttreatment of Maresin1 inhibits NLRP3 inflammasome activation via promotion of NLRP3 ubiquitination
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
KR101401744B1 (ko) Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물
Wu et al. Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion
US9072737B2 (en) tPA mutant in the treatment of acute brain injury and neurodegenerative disorders
AU2005203400B2 (en) Use of Alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia
Ezer et al. Neonatal purpura fulminans due to homozygous protein C deficiency
Sawhney et al. Delayed neurological manifestation in krait bites despite anti-snake venom therapy
HK1148198B (en) Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome
Yang et al. Effect of ulinastatin combined with intensive psychological intervention on anxiety, depression and inflammatory reaction in patients with acute respiratory distress syndrome
CN108315406A (zh) 一组用于检测血友病患者的fⅷ/fⅸ基因突变的引物及其应用
Aldayini et al. Hereditary angioedema in pediatric age: an overview
UA137135U (uk) Спосіб лікування хворих на хронічний панкреатит з метаболічним синдромом
HK1083601B (en) Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2832 DE 15-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.